Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
NSCLC
Biotech
iTeos drops one of 3 clinical assets from pipeline
iTeos is deprioritizing a phase 2 NSCLC asset after it failed to meet the biotech's bar for further investment.
Gabrielle Masson
Dec 12, 2024 3:10pm
FDA approves Novocure’s tumor field therapy for metastatic NSCLC
Oct 16, 2024 10:14am
Dupixent for cancer? Researchers test med as PD-1 booster
Dec 7, 2023 6:00am
Pfizer ends 5 programs amid cost-savings overhaul
Oct 31, 2023 11:21am
ASCO: Novocure's electric fields extend lung cancer survival
Jun 6, 2023 8:00am
Mirati's wait for next lung cancer med ends in phase 3 failure
May 24, 2023 4:00pm
